Skip to main content

Table 2 Mean changes in cognitive and functional scores for each quartile of the galantamine plasma concentration

From: Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

Galantamine plasma concentration after 2 months of treatment (n= 47)

Change in MMSE score after 2 monthsa

Galantamine plasma concentration after 6 months of treatment (n= 41)

Change in MMSE score after 6 monthsa

Change in ADAS-cog score after 6 monthsa

Change in IADL score after 6 monthsa

Quartile 1,

< 0.143 μmol/L

0.42 (-1.17, 2.01)

Quartile 1,

< 0.152 μmol/L

1.50 (-0.16, 3.16)

-1.90 (-5.51, 1.71)

-0.20 (-1.36, 0.96)

Quartile 2,

0.143 to 0.205 μmol/L

0.25 (-1.11, 1.61)

Quartile 2,

0.152 to 0.225 μmol/L

-0.36 (-1.33, 0.60)

0.36 (-1.12, 1.84)

-2.56 (-4.73, -0.38)

Quartile 3,

0.205 to 0.279 μmol/L

0.67 (-0.58, 1.92)

Quartile 3,

0.225 to 0.267 μmol/L

-0.60 (-2.19, 0.99)

-0.22 (-4.34, 3.90)

-2.89 (-6.36, 0.58)

Quartile 4,

> 0.279 μmol/L

-0.36 (-1.81, 1.09)

Quartile 4,

> 0.267 μmol/L

0.50 (-1.74, 2.74)

-0.20 (-2.25, 1.85)

0.00 (-1.15, 1.15)

  1. aMean (95% confidence interval). No significant differences in cognitive or functional changes were found among the patients in the different quartiles of the plasma concentration. ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination.